$CARM News

CARMILA: Information Concerning the Total Number of Voting Rights and Share

Carmila Makes its 2025 Universal Registration Document Available

Liberate Bio gains licences for myeloid-specific CAR design patents

Liberate Bio Secures Myeloid-Optimized CAR Design Licenses to Advance In Vivo CAR-M Programs

Carisma Announces Delisting from Nasdaq and SEC Deregistration

CARISMA Therapeutics Q3 EPS $1.07 Beats $(0.12) Estimate, Sales $45.250M Beat $3.771M Estimate

Carisma Therapeutics shares are trading higher after the company announced it will received a $5 million investment from Ocugen as part of a merger with Ocugen's subsidiary OrthoCelix.

Carisma Therapeutics shares are trading higher after the company announced it will received a $5 million investment from Ocugen as part of a merger with Ocugen's subsidiary OrthoCelix.

D. Boral Capital Maintains Buy on CARISMA Therapeutics, Maintains $1 Price Target

Carisma Therapeutics Shares Resume Trade

Trading Halt: Halt status updated at 7:55:00 AM ET: Quotation Resumption: News and Resumption Times

Trading Halt: Halted at 7:25:00 a.m. ET - Trading Halt: Halt News Pending

CARISMA Therapeutics Q1 EPS $(0.22) Misses $(0.10) Estimate, Sales $3.73M Inline

Carisma Therapeutics Full Year 2024 Earnings: Misses Expectations

Carisma Therapeutics shares are trading lower after D. Boral Capital cut its price target on the stock from $12 to $1.

D. Boral Capital Maintains Buy on CARISMA Therapeutics, Lowers Price Target to $1

Carisma Therapeutics Provides Corporate Updates

Carisma Therapeutics Approved Revised Operating Plan Focusing On Evaluating Strategic Alternatives While Reducing Operational Cash Burn

Carisma Therapeutics to Participate in H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference

Carisma Therapeutics to Participate in Oppenheimer 35th Annual Healthcare Life Sciences Conference